Sartorius Stedim Biotech SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013154002
EUR
165.00
-2.05 (-1.23%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

132.41 k

Shareholding (Dec 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With ROE of 7.54%, it has a Very Expensive valuation with a 3.82 Price to Book Value

  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -10.81%, its profits have risen by 35.9% ; the PEG ratio of the company is 1.4
2

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 16,142 Million ()

stock-summary
P/E

51.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.20%

stock-summary
Debt Equity

1.39

stock-summary
Return on Equity

7.54%

stock-summary
Price to Book

3.95

Revenue and Profits:
Net Sales:
772 Million
(Quarterly Results - Dec 2025)
Net Profit:
47 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.86%
0%
-19.86%
6 Months
-3.82%
0%
-3.82%
1 Year
-10.81%
0%
-10.81%
2 Years
-37.09%
0%
-37.09%
3 Years
-46.13%
0%
-46.13%
4 Years
-54.01%
0%
-54.01%
5 Years
-53.78%
0%
-53.78%

Sartorius Stedim Biotech SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
9.21%
EBIT Growth (5y)
0.86%
EBIT to Interest (avg)
7.14
Debt to EBITDA (avg)
1.85
Net Debt to Equity (avg)
0.52
Sales to Capital Employed (avg)
1.02
Tax Ratio
19.67%
Dividend Payout Ratio
25.28%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
24.27%
ROE (avg)
21.32%

Valuation key factors

Factor
Value
P/E Ratio
51
Industry P/E
Price to Book Value
3.82
EV to EBIT
32.04
EV to EBITDA
20.31
EV to Capital Employed
2.89
EV to Sales
5.95
PEG Ratio
1.41
Dividend Yield
1.24%
ROCE (Latest)
9.01%
ROE (Latest)
7.54%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 9.42% vs -5.28% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -27.05% vs -5.69% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "772.20",
          "val2": "705.70",
          "chgp": "9.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "198.90",
          "val2": "218.60",
          "chgp": "-9.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "47.00",
          "val2": "51.40",
          "chgp": "-8.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-70.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.20",
          "val2": "64.70",
          "chgp": "-27.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "148.90%",
          "val2": "198.00%",
          "chgp": "-4.91%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.74% vs 0.16% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 48.96% vs -42.92% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,967.50",
          "val2": "2,780.00",
          "chgp": "6.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "867.10",
          "val2": "721.50",
          "chgp": "20.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "152.70",
          "val2": "158.90",
          "chgp": "-3.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.60",
          "val2": "-41.80",
          "chgp": "65.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "265.90",
          "val2": "178.50",
          "chgp": "48.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "185.00%",
          "val2": "151.00%",
          "chgp": "3.40%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
772.20
705.70
9.42%
Operating Profit (PBDIT) excl Other Income
198.90
218.60
-9.01%
Interest
47.00
51.40
-8.56%
Exceptional Items
-70.00
0.00
Consolidate Net Profit
47.20
64.70
-27.05%
Operating Profit Margin (Excl OI)
148.90%
198.00%
-4.91%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 9.42% vs -5.28% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -27.05% vs -5.69% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2,967.50
2,780.00
6.74%
Operating Profit (PBDIT) excl Other Income
867.10
721.50
20.18%
Interest
152.70
158.90
-3.90%
Exceptional Items
-14.60
-41.80
65.07%
Consolidate Net Profit
265.90
178.50
48.96%
Operating Profit Margin (Excl OI)
185.00%
151.00%
3.40%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 6.74% vs 0.16% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 48.96% vs -42.92% in Dec 2024

stock-summaryCompany CV
About Sartorius Stedim Biotech SA stock-summary
stock-summary
Sartorius Stedim Biotech SA
Pharmaceuticals & Biotechnology
Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Company Coordinates stock-summary
Company Details
Avenue de Jouques, Zone Industrielle les Paluds, C.S. 9105, Aubagne Cedex, AUBAGNE None : 13781
Registrar Details